

Virginia Bellido

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6407384/publications.pdf>

Version: 2024-02-01

16
papers

317
citations

1162889

8
h-index

940416

16
g-index

16
all docs

16
docs citations

16
times ranked

393
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of COVID-19 lockdown on glycemc control in patients with type 1 diabetes. Diabetes Research and Clinical Practice, 2020, 166, 108348.	1.1	109
2	Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 2211-2216.	4.3	87
3	Time-in-range for monitoring glucose control: Is it time for a change?. Diabetes Research and Clinical Practice, 2021, 177, 108917.	1.1	21
4	The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond. Diabetes Therapy, 2021, 12, 2311-2327.	1.2	18
5	Inpatient Hyperglycemia Management and COVID-19. Diabetes Therapy, 2021, 12, 121-132.	1.2	17
6	COVID-19 and Diabetes. Journal of Clinical Medicine, 2021, 10, 5341.	1.0	13
7	Consecuencias de la COVID-19 sobre las personas con diabetes. Endocrinología, Diabetes Y Nutrición, 2020, 67, 355-356.	0.1	11
8	A Novel Mutation in a Patient with Hyperparathyroidism—Jaw Tumour Syndrome. Endocrine Pathology, 2016, 27, 142-146.	5.2	9
9	Consequences of COVID-19 on people with diabetes. Endocrinología y Diabetes Y Nutrición (English Ed), 2020, 67, 355-356.	0.1	7
10	Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study. Current Therapeutic Research, 2018, 89, 37-42.	0.5	6
11	Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes. Journal of Diabetes Science and Technology, 2023, 17, 1326-1336.	1.3	6
12	Description of a Cohort of Type 1 Diabetes Patients: Analysis of Comorbidities, Prevalence of Complications and Risk of Hypoglycemia. Journal of Clinical Medicine, 2022, 11, 1039.	1.0	5
13	Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications. Diabetes Therapy, 2022, 13, 873-888.	1.2	4
14	Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study. Drugs in Context, 2022, 11, 1-9.	1.0	2
15	Bone metastasis located on the foot as a clinical presentation of an adrenocortical carcinoma. Endocrinología y Diabetes Y Nutrición (English Ed), 2018, 65, 418-419.	0.1	1
16	Metástasis ósea en el pie como presentación clínic de un carcinoma suprarrenal. Endocrinología, Diabetes Y Nutrición, 2018, 65, 418-419.	0.1	1